{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:36:32Z","timestamp":1793046992453,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anti-amyloid \u03b2-peptide (A\u03b2) immunotherapy was developed to reduce amyloid plaque pathology and slow cognitive decline during progression of Alzheimer\u2019s disease. Efficient amyloid clearance has been proven in clinical trials testing anti-A\u03b2 antibodies, by their impact on cognitive endpoints correlating with the extent of amyloid removal. However, treatment is associated with adverse side effects, such as oedema and haemorrhages, which are potentially linked to the induced immune response. To improve the safety profile of these molecules, it is imperative to understand the consequences of anti-A\u03b2 antibody treatment on immune cell function. Here, we investigated the effects of long-term chronic anti-A\u03b2 treatment on amyloid plaque pathology and microglial response in the APP-SAA triple knock-in mouse model with an intervention paradigm early during amyloidogenesis. Long-term treatment with anti-A\u03b2 results in a robust and dose-dependent lowering of amyloid plaque pathology, with a higher efficiency for reducing diffuse over dense-core plaque deposition. Analysis of the CSF proteome indicates a reduction of markers for neurodegeneration including Tau and \u03b1-Synuclein, as well as immune-cell-related proteins. Bulk RNA-seq revealed a dose-dependent attenuation of disease-associated microglial (DAM) and glycolytic gene expression, which is supported by a parallel decrease of glucose uptake and protein levels of Triggering Receptor Expressed on Myeloid cells 2 (Trem2) protein, a major immune receptor involved in DAM activation of microglia. In contrast, DAM activation around residual plaques remains high, regardless of treatment dose. In addition, microglia surrounding residual plaques display a dose-dependent increase in microglial clustering and a selective increase in antigen-presenting and immune signalling proteins. These findings demonstrate that chronic early intervention by an anti-amyloid immunotherapy leads to a dose-dependent decrease in plaque formation, which is associated with lower brain-wide microglial DAM activation and neurodegeneration. Microglia at residual plaques still display a combined DAM and antigen-presenting phenotype that suggests a continued treatment response.<\/jats:p>","DOI":"10.1186\/s13024-025-00878-1","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T22:54:03Z","timestamp":1755644043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Early intervention anti-A\u03b2 immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques"],"prefix":"10.1186","volume":"20","author":[{"given":"Lis","family":"de Weerd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Eichholtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Gr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie L.","family":"Englert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonnet S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Warkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Nuscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Berghofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid F.","family":"Feiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Schlepckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan F.","family":"Lichtenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Lewcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Haass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"878_CR1","doi-asserted-by":"publisher","first-page":"e3001694","DOI":"10.1371\/journal.pbio.3001694","volume":"20","author":"C Haass","year":"2022","unstructured":"Haass C, Selkoe D. If amyloid drives alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? PLoS Biol. 2022;20:e3001694. https:\/\/doi.org\/10.1371\/journal.pbio.3001694","journal-title":"PLoS Biol"},{"key":"878_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"key":"878_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173\u20137. https:\/\/doi.org\/10.1038\/22124","journal-title":"Nature"},{"key":"878_CR4","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease. J Prev Alzheimer\u2019s Disease. 2022. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"878_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"878_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in early alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"878_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, et al. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15:11\u201320. https:\/\/doi.org\/10.1016\/j.nbd.2003.09.015","journal-title":"Neurobiol Dis"},{"key":"878_CR8","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","volume":"24","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144\u201351. https:\/\/doi.org\/10.1523\/JNEUROSCI.1090-04.2004","journal-title":"J Neurosci"},{"key":"878_CR9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553\u201362. https:\/\/doi.org\/10.1212\/01.WNL.0000159740.16984.3C","journal-title":"Neurology"},{"key":"878_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, et al. Detection and management of amyloid-related imaging abnormalities in patients with alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320. https:\/\/doi.org\/10.14283\/jpad.2022.21","journal-title":"J Prev Alzheimers Dis"},{"key":"878_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, et al. Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of alzheimer\u2019s disease. Mol Neurodegener. 2024;19:77. https:\/\/doi.org\/10.1186\/s13024-024-00758-0","journal-title":"Mol Neurodegener"},{"key":"878_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor X, et al. Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in alzheimer\u2019s disease mice. Mol Neurodegener. 2023;18:59. https:\/\/doi.org\/10.1186\/s13024-023-00649-w","journal-title":"Mol Neurodegener"},{"key":"878_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","volume":"22","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow K, Morenas-Rodriguez E, Hong S, Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for alzheimer\u2019s disease. Lancet Neurol. 2023;22:1048\u201360. https:\/\/doi.org\/10.1016\/S1474-4422(23)00247-8","journal-title":"Lancet Neurol"},{"key":"878_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","volume":"108","author":"JW Lewcock","year":"2020","unstructured":"Lewcock JW, et al. Emerging microglia biology defines novel therapeutic approaches for alzheimer\u2019s disease. Neuron. 2020;108:801\u201321. https:\/\/doi.org\/10.1016\/j.neuron.2020.09.029","journal-title":"Neuron"},{"key":"878_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, et al. TREM2 variants in alzheimer\u2019s disease. N Engl J Med. 2013;368:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1211851","journal-title":"N Engl J Med"},{"key":"878_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in alzheimer\u2019s disease. Mol Neurodegener. 2018;13:66. https:\/\/doi.org\/10.1186\/s13024-018-0298-9","journal-title":"Mol Neurodegener"},{"key":"878_CR17","doi-asserted-by":"publisher","unstructured":"Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566\u2013581 e569. https:\/\/doi.org\/10.1016\/j.immuni.2017.08.008","DOI":"10.1016\/j.immuni.2017.08.008"},{"key":"878_CR18","doi-asserted-by":"publisher","unstructured":"Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276\u20131290 e1217. https:\/\/doi.org\/10.1016\/j.cell.2017.05.018","DOI":"10.1016\/j.cell.2017.05.018"},{"key":"878_CR19","doi-asserted-by":"publisher","unstructured":"Zhao Y, et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron. 2018;97:1023\u20131031 e1027. https:\/\/doi.org\/10.1016\/j.neuron.2018.01.031","DOI":"10.1016\/j.neuron.2018.01.031"},{"key":"878_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","volume":"22","author":"S Parhizkar","year":"2019","unstructured":"Parhizkar S, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191\u2013204. https:\/\/doi.org\/10.1038\/s41593-018-0296-9","journal-title":"Nat Neurosci"},{"key":"878_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.15252\/embr.201743922","volume":"18","author":"F Mazaheri","year":"2017","unstructured":"Mazaheri F, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18:1186\u201398. https:\/\/doi.org\/10.15252\/embr.201743922","journal-title":"EMBO Rep"},{"key":"878_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, et al. Variant of TREM2 associated with the risk of alzheimer\u2019s disease. N Engl J Med. 2013;368:107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1211103","journal-title":"N Engl J Med"},{"key":"878_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodr\u00edguez","year":"2022","unstructured":"Morenas-Rodr\u00edguez E, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant alzheimer\u2019s disease: a longitudinal observational study. Lancet Neurol. 2022;21:329\u201341. https:\/\/doi.org\/10.1016\/s1474-4422(22)00027-8","journal-title":"Lancet Neurol"},{"key":"878_CR24","doi-asserted-by":"publisher","first-page":"e12308","DOI":"10.15252\/emmm.202012308","volume":"12","author":"M Ewers","year":"2020","unstructured":"Ewers M, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020;12:e12308. https:\/\/doi.org\/10.15252\/emmm.202012308","journal-title":"EMBO Mol Med"},{"key":"878_CR25","doi-asserted-by":"publisher","unstructured":"Ewers M, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer\u2019s disease. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aav6221","DOI":"10.1126\/scitranslmed.aav6221"},{"key":"878_CR26","doi-asserted-by":"publisher","unstructured":"Franzmeier N, et al. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Mol Neurodegeneration. 2020;15. https:\/\/doi.org\/10.1186\/s13024-020-00407-2","DOI":"10.1186\/s13024-020-00407-2"},{"key":"878_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.15252\/emmm.201606370","volume":"8","author":"X Xiang","year":"2016","unstructured":"Xiang X, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8:992\u20131004. https:\/\/doi.org\/10.15252\/emmm.201606370","journal-title":"EMBO Mol Med"},{"key":"878_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/AN20110018","volume":"3","author":"DM Wilcock","year":"2011","unstructured":"Wilcock DM, et al. Diverse inflammatory responses in transgenic mouse models of alzheimer\u2019s disease and the effect of immunotherapy on these responses. ASN Neuro. 2011;3:249\u201358. https:\/\/doi.org\/10.1042\/AN20110018","journal-title":"ASN Neuro"},{"key":"878_CR29","doi-asserted-by":"publisher","unstructured":"Cadiz MP, et al. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024;221. https:\/\/doi.org\/10.1084\/jem.20231363","DOI":"10.1084\/jem.20231363"},{"key":"878_CR30","doi-asserted-by":"publisher","unstructured":"Xiong M, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13. https:\/\/doi.org\/10.1126\/scitranslmed.abd7522","DOI":"10.1126\/scitranslmed.abd7522"},{"key":"878_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in alzheimer\u2019s disease. Nature. 2016;537:50\u20136. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"878_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JAD-200715","volume":"79","author":"J Bastrup","year":"2021","unstructured":"Bastrup J, et al. Anti-Abeta antibody aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic mouse model of alzheimer\u2019s disease. J Alzheimers Dis. 2021;79:249\u201365. https:\/\/doi.org\/10.3233\/JAD-200715","journal-title":"J Alzheimers Dis"},{"key":"878_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae345","author":"LA Welikovitch","year":"2024","unstructured":"Welikovitch LA, et al. Tau, synapse loss and gliosis progress in an alzheimer\u2019s mouse model after amyloid-beta immunotherapy. Brain. 2024. https:\/\/doi.org\/10.1093\/brain\/awae345","journal-title":"Brain"},{"key":"878_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03489-0","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita S, et al. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature. 2021. https:\/\/doi.org\/10.1038\/s41586-021-03489-0","journal-title":"Nature"},{"key":"878_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, et al. A plaque-specific antibody clears existing beta-amyloid plaques in alzheimer\u2019s disease mice. Neuron. 2012;76:908\u201320. https:\/\/doi.org\/10.1016\/j.neuron.2012.10.029","journal-title":"Neuron"},{"key":"878_CR36","doi-asserted-by":"publisher","unstructured":"Crehan H, et al. Effector function of anti-pyroglutamate-3 Abeta antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer\u2019s-like mice. Alzheimers Res Ther. 2020;12. https:\/\/doi.org\/10.1186\/s13195-019-0579-8","DOI":"10.1186\/s13195-019-0579-8"},{"key":"878_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s40478-020-01069-3","volume":"8","author":"V Laversenne","year":"2020","unstructured":"Laversenne V, et al. Anti-Abeta antibodies bound to neuritic plaques enhance microglia activity and mitigate Tau pathology. Acta Neuropathol Commun. 2020;8:198. https:\/\/doi.org\/10.1186\/s40478-020-01069-3","journal-title":"Acta Neuropathol Commun"},{"key":"878_CR38","doi-asserted-by":"publisher","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, et al. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci. 2016;36:12549\u201358. https:\/\/doi.org\/10.1523\/JNEUROSCI.2080-16.2016","journal-title":"J Neurosci"},{"key":"878_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575\u201388. https:\/\/doi.org\/10.3233\/JAD-140741","journal-title":"J Alzheimers Dis"},{"key":"878_CR40","doi-asserted-by":"publisher","unstructured":"Wilcock DM, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1. https:\/\/doi.org\/10.1186\/1742-2094-1-24","DOI":"10.1186\/1742-2094-1-24"},{"key":"878_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey ED, et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 2022;144:143\u201353. https:\/\/doi.org\/10.1007\/s00401-022-02433-4","journal-title":"Acta Neuropathol"},{"key":"878_CR42","doi-asserted-by":"publisher","first-page":"14156","DOI":"10.1523\/JNEUROSCI.4147-08.2008","volume":"28","author":"J Koenigsknecht-Talboo","year":"2008","unstructured":"Koenigsknecht-Talboo J, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008;28:14156\u201364. https:\/\/doi.org\/10.1523\/JNEUROSCI.4147-08.2008","journal-title":"J Neurosci"},{"key":"878_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40035-022-00333-x","volume":"11","author":"C Kong","year":"2022","unstructured":"Kong C, et al. Enhanced delivery of a low dose of aducanumab via FUS in 5xFAD mice, an AD model. Transl Neurodegener. 2022;11:57. https:\/\/doi.org\/10.1186\/s40035-022-00333-x","journal-title":"Transl Neurodegener"},{"key":"878_CR44","doi-asserted-by":"publisher","unstructured":"Pizzo ME, et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science . 2025;389:eads3204. https:\/\/doi.org\/10.1126\/science.ads3204","DOI":"10.1126\/science.ads3204"},{"key":"878_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"D J Klionsky","year":"2016","unstructured":"J Klionsky D, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1\u2013222. https:\/\/doi.org\/10.1080\/15548627.2015.1100356","journal-title":"Autophagy"},{"key":"878_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03574-1","author":"L van Olst","year":"2025","unstructured":"van Olst L, et al. Microglial mechanisms drive amyloid-beta clearance in immunized patients with alzheimer\u2019s disease. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03574-1","journal-title":"Nat Med"},{"key":"878_CR47","doi-asserted-by":"publisher","unstructured":"Xia D, et al. Novel app knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegener. 2022;17. https:\/\/doi.org\/10.1186\/s13024-022-00547-7","DOI":"10.1186\/s13024-022-00547-7"},{"key":"878_CR48","doi-asserted-by":"publisher","unstructured":"Kariolis MS, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12. https:\/\/doi.org\/10.1126\/scitranslmed.aay1359","DOI":"10.1126\/scitranslmed.aay1359"},{"key":"878_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01240-0","author":"B van Lengerich","year":"2023","unstructured":"van Lengerich B, et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in alzheimer\u2019s disease models. Nat Neurosci. 2023. https:\/\/doi.org\/10.1038\/s41593-022-01240-0","journal-title":"Nat Neurosci"},{"key":"878_CR50","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/mcb.9.3.1165-1172.1989","volume":"9","author":"RM Hudziak","year":"1989","unstructured":"Hudziak RM, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9:1165\u201372. https:\/\/doi.org\/10.1128\/mcb.9.3.1165-1172.1989","journal-title":"Mol Cell Biol"},{"key":"878_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fnins.2016.00045","volume":"10","author":"F Overhoff","year":"2016","unstructured":"Overhoff F, et al. Automated spatial brain normalization and hindbrain white matter reference tissue give improved [(18)F]-Florbetaben PET quantitation in alzheimer\u2019s model mice. Front Neurosci. 2016;10:45. https:\/\/doi.org\/10.3389\/fnins.2016.00045","journal-title":"Front Neurosci"},{"key":"878_CR52","doi-asserted-by":"publisher","unstructured":"Reifschneider A, et al. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO J. 2022;e109108. https:\/\/doi.org\/10.15252\/embj.2021109108","DOI":"10.15252\/embj.2021109108"},{"key":"878_CR53","first-page":"277","volume":"48","author":"WK Schiffer","year":"2007","unstructured":"Schiffer WK, Mirrione MM, Dewey SL. Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents. J Nucl Med. 2007;48:277\u201387.","journal-title":"J Nucl Med"},{"key":"878_CR54","doi-asserted-by":"publisher","first-page":"eabe5640","DOI":"10.1126\/scitranslmed.abe5640","volume":"13","author":"X Xiang","year":"2021","unstructured":"Xiang X, et al. Microglial activation States drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13:eabe5640. https:\/\/doi.org\/10.1126\/scitranslmed.abe5640","journal-title":"Sci Transl Med"},{"key":"878_CR55","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","volume":"10","author":"J Logan","year":"1990","unstructured":"Logan J, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11\u00a0C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740\u20137. https:\/\/doi.org\/10.1038\/jcbfm.1990.127","journal-title":"J Cereb Blood Flow Metab"},{"key":"878_CR56","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.neuroscience.2005.07.014","volume":"135","author":"Y Ma","year":"2005","unstructured":"Ma Y, et al. A three-dimensional digital atlas database of the adult C57BL\/6J mouse brain by magnetic resonance microscopy. Neuroscience. 2005;135:1203\u201315. https:\/\/doi.org\/10.1016\/j.neuroscience.2005.07.014","journal-title":"Neuroscience"},{"key":"878_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13024-023-00657-w","volume":"18","author":"I Pesamaa","year":"2023","unstructured":"Pesamaa I, et al. A microglial activity state biomarker panel differentiates FTD-granulin and alzheimer\u2019s disease patients from controls. Mol Neurodegener. 2023;18:70. https:\/\/doi.org\/10.1186\/s13024-023-00657-w","journal-title":"Mol Neurodegener"},{"key":"878_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2967\/jnumed.120.261858","volume":"63","author":"G Biechele","year":"2022","unstructured":"Biechele G, et al. Glitter in the darkness? Nonfibrillar beta-Amyloid plaque components significantly impact the beta-Amyloid PET signal in mouse models of alzheimer disease. J Nucl Med. 2022;63:117\u201324. https:\/\/doi.org\/10.2967\/jnumed.120.261858","journal-title":"J Nucl Med"},{"key":"878_CR59","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","volume":"34","author":"F Liao","year":"2014","unstructured":"Liao F, et al. Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis. J Neurosci. 2014;34:7281\u201392. https:\/\/doi.org\/10.1523\/JNEUROSCI.0646-14.2014","journal-title":"J Neurosci"},{"key":"878_CR60","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"key":"878_CR61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41592-019-0650-1","volume":"CLIJ","author":"R Haase","year":"2020","unstructured":"Haase R, et al. GPU-accelerated image processing for everyone. Nat Methods 17. 2020;CLIJ:5\u20136. https:\/\/doi.org\/10.1038\/s41592-019-0650-1","journal-title":"Nat Methods 17"},{"key":"878_CR62","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: https:\/\/www.R-project.org\/. (2023)."},{"key":"878_CR63","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/bioinformatics\/btt276","volume":"29","author":"J Ollion","year":"2013","unstructured":"Ollion J, Cochennec J, Loll F, Escude C, Boudier T. TANGO: a generic tool for high-throughput 3D image analysis for studying nuclear organization. Bioinformatics. 2013;29:1840\u20131. https:\/\/doi.org\/10.1093\/bioinformatics\/btt276","journal-title":"Bioinformatics"},{"key":"878_CR64","doi-asserted-by":"publisher","unstructured":"napari. A multi-dimensional image viewer for python. https:\/\/doi.org\/10.5281\/zenodo.3555620 (2019).","DOI":"10.5281\/zenodo.3555620"},{"key":"878_CR65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature14864","volume":"526","author":"M Willem","year":"2015","unstructured":"Willem M, et al. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526:443\u20137. https:\/\/doi.org\/10.1038\/nature14864","journal-title":"Nature"},{"key":"878_CR66","doi-asserted-by":"publisher","first-page":"e11227","DOI":"10.15252\/emmm.201911227","volume":"12","author":"K Schlepckow","year":"2020","unstructured":"Schlepckow K, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12:e11227. https:\/\/doi.org\/10.15252\/emmm.201911227","journal-title":"EMBO Mol Med"},{"key":"878_CR67","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes CS, et al. Single-pot, solid-phase-enhanced sample Preparation for proteomics experiments. Nat Protoc. 2019;14:68\u201385. https:\/\/doi.org\/10.1038\/s41596-018-0082-x","journal-title":"Nat Protoc"},{"key":"878_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17:41\u20134. https:\/\/doi.org\/10.1038\/s41592-019-0638-x","journal-title":"Nat Methods"},{"key":"878_CR69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, et al. The perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731\u201340. https:\/\/doi.org\/10.1038\/nmeth.3901","journal-title":"Nat Methods"},{"key":"878_CR70","doi-asserted-by":"publisher","unstructured":"Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences. 2001;98:5116\u20135121. https:\/\/doi.org\/10.1073\/pnas.091062498","DOI":"10.1073\/pnas.091062498"},{"key":"878_CR71","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0439-x","journal-title":"Nat Biotechnol"},{"key":"878_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"key":"878_CR73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139. https:\/\/doi.org\/10.1038\/nmeth.4197","journal-title":"Nat Methods"},{"key":"878_CR74","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso P, et al. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35:316\u20139. https:\/\/doi.org\/10.1038\/nbt.3820","journal-title":"Nat Biotechnol"},{"key":"878_CR75","doi-asserted-by":"publisher","unstructured":"Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29. https:\/\/doi.org\/10.1186\/gb-2014-15-2-r29","DOI":"10.1186\/gb-2014-15-2-r29"},{"key":"878_CR76","doi-asserted-by":"publisher","unstructured":"Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11(R25). https:\/\/doi.org\/10.1186\/gb-2010-11-3-r25","DOI":"10.1186\/gb-2010-11-3-r25"},{"key":"878_CR77","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"},{"key":"878_CR78","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B: Stat Methodol. 1995;57:289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"878_CR79","doi-asserted-by":"publisher","DOI":"10.1101\/060012","author":"G Korotkevich","year":"2019","unstructured":"Korotkevich G, et al. Fast gene set enrichment analysis. BioRxiv. 2019. https:\/\/doi.org\/10.1101\/060012","journal-title":"BioRxiv"},{"key":"878_CR80","doi-asserted-by":"publisher","unstructured":"Logan T et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184:4651\u20134668 e4625. https:\/\/doi.org\/10.1016\/j.cell.2021.08.002","DOI":"10.1016\/j.cell.2021.08.002"},{"key":"878_CR81","doi-asserted-by":"publisher","unstructured":"Ahlmann-Eltze C, Patil I, ggsignif. R Package for Displaying Significance Brackets for \u2018ggplot2\u2019. https:\/\/doi.org\/10.31234\/osf.io\/7awm6","DOI":"10.31234\/osf.io\/7awm6"},{"key":"878_CR82","doi-asserted-by":"publisher","unstructured":"Wickham H, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4. https:\/\/doi.org\/10.21105\/joss.01686","DOI":"10.21105\/joss.01686"},{"key":"878_CR83","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/BF00294259","volume":"89","author":"R Mena","year":"1995","unstructured":"Mena R, Edwards P, Perez-Olvera O, Wischik CM. Monitoring pathological assembly of Tau and beta-amyloid proteins in alzheimer\u2019s disease. Acta Neuropathol. 1995;89:50\u20136. https:\/\/doi.org\/10.1007\/BF00294259","journal-title":"Acta Neuropathol"},{"key":"878_CR84","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/glia.20710","volume":"56","author":"S Frank","year":"2008","unstructured":"Frank S, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438\u201347. https:\/\/doi.org\/10.1002\/glia.20710","journal-title":"Glia"},{"key":"878_CR85","doi-asserted-by":"publisher","unstructured":"Sebastian Monasor L, et al. Fibrillar Abeta triggers microglial proteome alterations and dysfunction in alzheimer mouse models. Elife. 2020;9. https:\/\/doi.org\/10.7554\/eLife.54083","DOI":"10.7554\/eLife.54083"},{"key":"878_CR86","doi-asserted-by":"publisher","first-page":"100281","DOI":"10.1016\/j.jbc.2021.100281","volume":"296","author":"S Devkota","year":"2021","unstructured":"Devkota S, Williams TD, Wolfe MS. Familial alzheimer\u2019s disease mutations in amyloid protein precursor alter proteolysis by gamma-secretase to increase amyloid beta-peptides of >\/=45 residues. J Biol Chem. 2021;296:100281. https:\/\/doi.org\/10.1016\/j.jbc.2021.100281","journal-title":"J Biol Chem"},{"key":"878_CR87","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3233\/JAD-131373","volume":"39","author":"J Reinert","year":"2014","unstructured":"Reinert J, et al. Abeta38 in the brains of patients with sporadic and familial alzheimer\u2019s disease and transgenic mouse models. J Alzheimers Dis. 2014;39:871\u201381. https:\/\/doi.org\/10.3233\/JAD-131373","journal-title":"J Alzheimers Dis"},{"key":"878_CR88","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1038\/ncomms3246","volume":"4","author":"M Dimitrov","year":"2013","unstructured":"Dimitrov M, et al. Alzheimer\u2019s disease mutations in APP but not gamma-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat Commun. 2013;4:2246. https:\/\/doi.org\/10.1038\/ncomms3246","journal-title":"Nat Commun"},{"key":"878_CR89","doi-asserted-by":"publisher","unstructured":"Arndt JW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep. 2018;8. https:\/\/doi.org\/10.1038\/s41598-018-24501-0","DOI":"10.1038\/s41598-018-24501-0"},{"key":"878_CR90","doi-asserted-by":"publisher","first-page":"e0116678","DOI":"10.1371\/journal.pone.0116678","volume":"10","author":"M Brendel","year":"2015","unstructured":"Brendel M, et al. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS ONE. 2015;10:e0116678. https:\/\/doi.org\/10.1371\/journal.pone.0116678","journal-title":"PLoS ONE"},{"key":"878_CR91","doi-asserted-by":"publisher","first-page":"108032","DOI":"10.1016\/j.jbc.2024.108032","volume":"301","author":"T Klingstedt","year":"2025","unstructured":"Klingstedt T, et al. Dual-ligand fluorescence microscopy enables chronological and Spatial histological assignment of distinct amyloid-beta deposits. J Biol Chem. 2025;301:108032. https:\/\/doi.org\/10.1016\/j.jbc.2024.108032","journal-title":"J Biol Chem"},{"key":"878_CR92","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"878_CR93","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s43587-024-00611-5","volume":"4","author":"DJ Selkoe","year":"2024","unstructured":"Selkoe DJ. The advent of alzheimer treatments will change the trajectory of human aging. Nat Aging. 2024;4:453\u201363. https:\/\/doi.org\/10.1038\/s43587-024-00611-5","journal-title":"Nat Aging"},{"key":"878_CR94","doi-asserted-by":"publisher","unstructured":"Chen Y, Colonna M. Microglia in Alzheimer\u2019s disease at single-cell level. Are there common patterns in humans and mice? J Exp Med. 2021;218. https:\/\/doi.org\/10.1084\/jem.20202717","DOI":"10.1084\/jem.20202717"},{"key":"878_CR95","doi-asserted-by":"publisher","unstructured":"Ulland TK et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer\u2019s Disease. Cell. 2017;170:649\u2013663 e613. https:\/\/doi.org\/10.1016\/j.cell.2017.07.023","DOI":"10.1016\/j.cell.2017.07.023"},{"key":"878_CR96","doi-asserted-by":"publisher","unstructured":"Feiten AF et al. TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism. https:\/\/doi.org\/10.1101\/2024.07.18.604115 (2024).","DOI":"10.1101\/2024.07.18.604115"},{"key":"878_CR97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L Soderberg","year":"2023","unstructured":"Soderberg L, et al. Lecanemab, aducanumab, and Gantenerumab - Binding profiles to different forms of Amyloid-Beta might explain efficacy and side effects in clinical trials for alzheimer\u2019s disease. Neurotherapeutics. 2023;20:195\u2013206. https:\/\/doi.org\/10.1007\/s13311-022-01308-6","journal-title":"Neurotherapeutics"},{"key":"878_CR98","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000090368","volume":"2","author":"C Hock","year":"2005","unstructured":"Hock C, Nitsch RM. Clinical observations with AN-1792 using TAPIR analyses. Neurodegener Dis. 2005;2:273\u20136. https:\/\/doi.org\/10.1159\/000090368","journal-title":"Neurodegener Dis"},{"key":"878_CR99","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, et al. Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388:478\u20139. https:\/\/doi.org\/10.1056\/NEJMc2215148","journal-title":"N Engl J Med"},{"key":"878_CR100","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, et al. Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with Lecanemab for alzheimer\u2019s disease. Nat Commun. 2023;14:8220. https:\/\/doi.org\/10.1038\/s41467-023-43933-5","journal-title":"Nat Commun"},{"key":"878_CR101","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13195-024-01463-2","volume":"16","author":"W Liu","year":"2024","unstructured":"Liu W, et al. Cerebrospinal fluid alpha-synuclein adds the risk of cognitive decline and is associated with Tau pathology among non-demented older adults. Alzheimers Res Ther. 2024;16:103. https:\/\/doi.org\/10.1186\/s13195-024-01463-2","journal-title":"Alzheimers Res Ther"},{"key":"878_CR102","doi-asserted-by":"publisher","first-page":"40263","DOI":"10.1038\/srep40263","volume":"7","author":"NK Majbour","year":"2017","unstructured":"Majbour NK, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable alzheimer\u2019s disease. Sci Rep. 2017;7:40263. https:\/\/doi.org\/10.1038\/srep40263","journal-title":"Sci Rep"},{"key":"878_CR103","doi-asserted-by":"publisher","unstructured":"Uytterhoeven V, Verstreken P, Nachman E. Synaptic sabotage: how Tau and alpha-Synuclein undermine synaptic health. J Cell Biol. 2025;224. https:\/\/doi.org\/10.1083\/jcb.202409104","DOI":"10.1083\/jcb.202409104"},{"key":"878_CR104","doi-asserted-by":"publisher","first-page":"578342","DOI":"10.1016\/j.jneuroim.2024.578342","volume":"390","author":"S Fruhwurth","year":"2024","unstructured":"Fruhwurth S, Zetterberg H, Paludan SR. Microglia and amyloid plaque formation in alzheimer\u2019s disease - Evidence, possible mechanisms, and future challenges. J Neuroimmunol. 2024;390:578342. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578342","journal-title":"J Neuroimmunol"},{"key":"878_CR105","doi-asserted-by":"publisher","unstructured":"Stern AM, et al. Abundant Abeta fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer\u2019s disease brains. Neuron. 2023;111:2012\u20132020 e2014. https:\/\/doi.org\/10.1016\/j.neuron.2023.04.007","DOI":"10.1016\/j.neuron.2023.04.007"},{"key":"878_CR106","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015;6:6176. https:\/\/doi.org\/10.1038\/ncomms7176","journal-title":"Nat Commun"},{"key":"878_CR107","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-022-00966-0","volume":"14","author":"JC Dodge","year":"2022","unstructured":"Dodge JC, et al. Glucosylceramide synthase Inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:19. https:\/\/doi.org\/10.1186\/s13195-022-00966-0","journal-title":"Alzheimers Res Ther"},{"key":"878_CR108","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07358-0","author":"AD Dahlen","year":"2025","unstructured":"Dahlen AD, et al. PET imaging of TREM2 in amyloid-beta induced neuroinflammation. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07358-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"878_CR109","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s43587-023-00491-1","volume":"3","author":"SF Lau","year":"2023","unstructured":"Lau SF, et al. The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates alzheimer\u2019s disease pathology. Nat Aging. 2023;3:1219\u201336. https:\/\/doi.org\/10.1038\/s43587-023-00491-1","journal-title":"Nat Aging"},{"key":"878_CR110","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41593-019-0566-1","volume":"23","author":"J Marschallinger","year":"2020","unstructured":"Marschallinger J, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and Proinflammatory state in the aging brain. Nat Neurosci. 2020;23:194\u2013208. https:\/\/doi.org\/10.1038\/s41593-019-0566-1","journal-title":"Nat Neurosci"},{"key":"878_CR111","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/343336a0","volume":"343","author":"CH Hannum","year":"1990","unstructured":"Hannum CH, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990;343:336\u201340. https:\/\/doi.org\/10.1038\/343336a0","journal-title":"Nature"},{"key":"878_CR112","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design. Immunity. 2023;56:1485\u20131501 e1487. https:\/\/doi.org\/10.1016\/j.immuni.2023.05.014","DOI":"10.1016\/j.immuni.2023.05.014"},{"key":"878_CR113","doi-asserted-by":"publisher","first-page":"10791","DOI":"10.1038\/ncomms10791","volume":"7","author":"RG Iannitti","year":"2016","unstructured":"Iannitti RG, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat Commun. 2016;7:10791. https:\/\/doi.org\/10.1038\/ncomms10791","journal-title":"Nat Commun"},{"key":"878_CR114","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:235. https:\/\/doi.org\/10.1186\/s13195-024-01599-1","journal-title":"Alzheimers Res Ther"},{"key":"878_CR115","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12974-020-01915-0","volume":"17","author":"BR Price","year":"2020","unstructured":"Price BR, et al. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation. 2020;17:238. https:\/\/doi.org\/10.1186\/s12974-020-01915-0","journal-title":"J Neuroinflammation"},{"key":"878_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-025-01955-w","author":"J Groh","year":"2025","unstructured":"Groh J, et al. Microglia activation orchestrates CXCL10-mediated CD8(+) T cell recruitment to promote aging-related white matter degeneration. Nat Neurosci. 2025. https:\/\/doi.org\/10.1038\/s41593-025-01955-w","journal-title":"Nat Neurosci"},{"key":"878_CR117","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, et al. The AHEAD 3\u201345 study: design of a prevention trial for alzheimer\u2019s disease. Alzheimers Dement. 2023;19:1227\u201333. https:\/\/doi.org\/10.1002\/alz.12748","journal-title":"Alzheimers Dement"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00878-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00878-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00878-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T22:54:05Z","timestamp":1755644045000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00878-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00878-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments and handling of mice was performed in compliance with the German animal welfare law and with approval from the Government of Upper Bavaria (animal license: ROB-55.2-2532.Vet_02-18-32).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"C.H. and K.S. collaborate with Denali Therapeutics Inc. and C.H. is a member of the advisory boards of AviadoBio, Cure Ventures and Curie.Bio. M.B. is a member of the Neuroimaging Committee of the EANM. M.B. has received speaker honoraria from Roche, GE Healthcare, Iba, and Life Molecular Imaging; has advised Life Molecular Imaging and GE healthcare; and is currently on the advisory board of MIAC. T.S., C.H., S.S.D., V.W., D.X., J.W.L. and K.M.M. are full time employees of Denali Therapeutics Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}